We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+21.26%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$3.77B
AUM Growth
+$720M
(+24%)
Cap. Flow
+$280M
Cap. Flow
% of AUM
7.43%
Top 10 Holdings %
Top 10 Hldgs %
22.38%
Holding
294
New
116
Increased
45
Reduced
52
Closed
77
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$115M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$93.9M |
| 3 |
NXP Semiconductors
NXPI
|
+$57.1M |
| 4 |
Eli Lilly
LLY
|
+$51.1M |
| 5 |
Qorvo
QRVO
|
+$47.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$72.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$66.5M |
| 3 |
Amazon
AMZN
|
+$65.6M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$58.8M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$53.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.9% |
| 2 | Technology | 32.83% |
| 3 | Communication Services | 8.98% |
| 4 | Financials | 3.92% |
| 5 | Consumer Discretionary | 3.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Immatics
IMTX
$1.27B
| $5.52M | 0.15% |
511,256
+324,665
| +174% | +$3.42M |
|
152
C4 Therapeutics
CCCC
$399M
| $5.51M | 0.15% |
+166,323
| New | +$4.82M |
|
153
Exelixis
EXEL
$14.1B
| $5.47M | 0.15% |
272,800
-1,039,087
| -79% | -$21.8M |
|
154
Nurix Therapeutics
NRIX
$2.57B
| $5.3M | 0.14% |
161,211
+17,124
| +12% | +$567K |
|
|
CHMA
155
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $5.29M | 0.14% |
1,216,512
-111,745
| -8% | -$465K |
|
156
Walt Disney
DIS
$170B
| $5.21M | 0.14% |
+28,769
| New | +$4.13M |
|
157
Orchestra BioMed
OBIO
$254M
| $5.17M | 0.14% |
403,699
+3,699
| +0.9% | +$42.2K |
|
158
American Well
AMWL
$175M
| $5.16M | 0.14% |
10,176
-407
| -4% | -$236K |
|
|
MTEM
159
DELISTED
Molecular Templates, Inc.
MTEM
| $4.86M | 0.13% |
34,511
-39,543
| -53% | -$5.84M |
|
160
GoodRx Holdings
GDRX
$1.14B
| $4.62M | 0.12% |
114,520
+52,020
| +83% | +$2.39M |
|
|
FSDC
161
DELISTED
FS Development Corp. Class A Common Stock
FSDC
| $4.55M | 0.12% |
413,332
| – | – |
|
162
Interparfums
IPAR
$4.11B
| $4.43M | 0.12% |
+73,273
| New | +$3.69M |
|
163
4D Molecular Therapeutics
FDMT
$534M
| $4.29M | 0.11% |
+103,453
| New | +$4.27M |
|
|
MOTV.U
164
DELISTED
Motive Capital Corp Units, each consisting of one Class A ordinary share, and one-third of one redee
MOTV.U
| $4.22M | 0.11% |
+400,000
| New | +$4.14M |
|
|
APTO
165
DELISTED
Aptose Biosciences, Inc.
APTO
| $4.21M | 0.11% |
2,138
-1,490
| -41% | -$3.5M |
|
166
Envista
NVST
$4.55B
| $4.18M | 0.11% |
123,855
-33,766
| -21% | -$979K |
|
167
AT&T
T
$160B
| $4.05M | 0.11% |
+186,602
| New | +$4.02M |
|
168
HP
HPQ
$26.3B
| $4.05M | 0.11% |
+164,698
| New | +$3.46M |
|
169
Sutro Biopharma
STRO
$428M
| $3.96M | 0.1% |
+18,218
| New | +$3.02M |
|
170
Coty
COTY
$2.59B
| $3.94M | 0.1% |
+561,433
| New | +$2.89M |
|
171
e.l.f. Beauty
ELF
$5.23B
| $3.7M | 0.1% |
+147,026
| New | +$3.16M |
|
172
Certara
CERT
$1.2B
| $3.6M | 0.1% |
+106,665
| New | +$3.91M |
|
173
Lufax Holding
LU
$1.31B
| $3.55M | 0.09% |
+62,500
| New | +$3.74M |
|
|
MKTWW
174
DELISTED
MarketWise, Inc. Warrant
MKTWW
| $3.43M | 0.09% |
2,004,385
| – | – |
|
|
YQ
175
17 Education & Technology Group
YQ
$19.9M
| $3.39M | 0.09% |
+13,232
| New | +$3.83M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q4 2020 Portfolio in Review
As of Q4 2020, Woodline Partners held 294 positions worth $3.77B, up 24% from $3.05B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Woodline Partners deployed $280M of net new capital in Q4 2020, opening 116 new positions and adding to 45 existing holdings. Its largest new stake was Amgen: 500,520 shares worth $115M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $58.8M trimmed.
- Woodline Partners's largest Q4 2020 buy was Amgen: 500,520 shares worth $115M.
- Woodline Partners added most to Eli Lilly in Q4 2020, an estimated $51.1M increase.
- Woodline Partners's biggest Q4 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $58.8M.
- Woodline Partners fully exited Microchip Technology in Q4 2020, selling an estimated $72.6M.
- Woodline Partners's ten largest holdings make up 22% of its $3.77B portfolio in Q4 2020.
- Woodline Partners opened 116 new positions and closed 77 in Q4 2020.
- Woodline Partners's portfolio value rose 24% quarter-over-quarter to $3.77B.
Based on Woodline Partners's 13F filing for Q4 2020, filed 16 Feb 2021.